Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique called CEST-MRI (Chemical Exchange Saturation Transfer Magnetic Resonance Imaging) to help better diagnose prostate cancer in men who have elevated PSA levels, which is a common indicator of possible prostate issues. Prostate cancer is a significant health concern, and while current imaging methods can help, they often leave some uncertainties. By using CEST-MRI, the researchers hope to provide more detailed information about the cancer's characteristics—such as whether it is low, intermediate, or high grade—potentially reducing the need for invasive procedures like biopsies.

To participate in this study, men aged 18 and older who have a suspected diagnosis of prostate cancer due to increased PSA levels may be eligible. Participants should not have received any prior cancer treatments and must be able to understand and read French. Throughout the trial, participants will undergo various imaging tests, and their results will be compared to the standard Gleason score obtained from prostate biopsies to see how well CEST-MRI can predict cancer characteristics. This research could lead to improved diagnosis and better treatment decisions for patients with prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• Patients will be included:
• • aged over 18
• • with suspected prostate cancer identified by an increase in blood PSA concentration
• • naïve to chemotherapy, radiotherapy or hormonal therapy
• • affiliated to a Social Security system
• • able to give informed consent to participate in research
• • understanding and reading French well
• Exclusion Criteria:
• Patients will be excluded:
• • refusing to participate in the study
• • with impaired understanding, under guardianship/curatorship/deprived of liberty
• • presenting "contraindications" to an MRI examination (with administration of a gadolinium chelate): presence of metal parts in the body (electronic devices such as a cardiac pacemaker, a neurostimulator, a cochlear implant, prostheses, intra foreign bodies ocular...), claustrophobia, obesity
• * at risk:
• • 1. . history of allergy to gadolinium (contrast product necessary for performing the multiparmatric MRI planned in the routine care pathway
• • 2. . history of hypersensitivity to gadoteric acid or gadoline contrast agents, meglumine
• • during a period of exclusion from another study